Phase II Trial of Nivolumab, an Immune Checkpoint Inhibitor, Alone or in Combination With Oral Decitabine/Tetrahydrouridine as Second Line Therapy for Non-Small Cell Lung Cancer
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 10 Apr 2017
At a glance
- Drugs Decitabine (Primary) ; Nivolumab (Primary) ; Tetrahydrouridine (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms PRECISE
- 07 Jun 2017 Biomarkers information updated
- 31 Mar 2017 Planned initiation date changed from 1 Feb 2017 to 30 Jun 2017.
- 10 Oct 2016 Planned number of patients changed from 66 to 60.